Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate

CONTEXT: In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Endocrinol Metab
Auteurs principaux: Tsai, Joy N., Zhu, Yuli, Foley, Katelyn, Lee, Hang, Burnett-Bowie, Sherri-Ann, Neer, Robert M., Leder, Benjamin Z.
Format: Artigo
Langue:Inglês
Publié: Endocrine Society 2015
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5393530/
https://ncbi.nlm.nih.gov/pubmed/25933031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-1541
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires